Interleukin-12 is associated with the in vivo anti-tumor effect of mistletoe extracts in B16 mouse melanoma

Cancer Letters

Volumn 243, Issue 1, 2006, Pages 32-37

  Duong Van Huyen, Jean Paul ^a,b   Delignat, Sandrine ^a   Bayry, Jagadeesh ^a   Kazatchkine, Michel D ^a   Bruneval, Patrick ^b   Nicoletti, Antonino ^a   Kaveri, Srini V ^a  

^a INSERM   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

IL 12; Immunomodulation; Melanoma; Mistletoe

Indexed keywords

INTERLEUKIN 12; VISCUM ALBUM EXTRACT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; UPREGULATION; VISCUM ALBUM;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; INTERLEUKIN-12; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTATION; PHYTOTHERAPY; PLANT EXTRACTS; PLANT LECTINS; SPLEEN; VISCUM ALBUM;

VISCUM ALBUM;

EID: 33749257279     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.11.016     Document Type: Article

References (28)

1. Stirpe F., Sandvig K., Olsnes S., and Pihl A. Action of viscumin, a toxic lectin from mistletoe, on cells in culture. J. Biol. Chem. 257 (1982) 13271-13277
2. Eschenburg S., Krauspenhaar R., Mikhailov A., Stoeva S., Betzel C., and Voelter W. Primary structure and molecular modeling of mistletoe lectin I from Viscum album. Biochem. Biophys. Res. Commun. 247 (1998) 367-372
3. Burger A.M., Mengs U., Schuler J.B., Fiebig H., and Fiebig H.H. Anticancer activity of an aqueous mistletoe extract (AME) in syngeneic murine tumor models. Anticancer Res. 21 (2001) 1965-1968
4. Bantel H., Engels I.H., Voelter W., Schulze-Osthoff K., and Wesselborg S. Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis. Cancer Res. 59 (1999) 2083-2090
5. Braun J.M., Ko H.L., Schierholz J.M., and Beuth J. Standardized mistletoe extract augments immune response and down-regulates local and metastatic tumor growth in murine models. Anticancer Res. 22 (2002) 4187-4190
6. Hajto T., Hostanska K., and Gabius H.J. Modulatory potency of the beta-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. Cancer Res. 49 (1989) 4803-4808
7. Park W.B., Lyu S.Y., Kim J.H., Choi S.H., Chung H.K., Ahn S.H., et al. Inhibition of tumor growth and metastasis by Korean mistletoe lectin is associated with apoptosis and antiangiogenesis. Cancer Biother. Radiopharm. 16 (2001) 439-447
8. Ribereau-Gayon G., Dumont S., Muller C., Jung M.L., Poindron P., and Anton R. Mistletoe lectins I, II and III induce the production of cytokines by cultured human monocytes. Cancer Lett. 109 (1996) 33-38
9. Van Huyen J.P., Bayry J., Delignat S., Gaston A.T., Michel O., Bruneval P., et al. Induction of apoptosis of endothelial cells by Viscum album: a role for anti-tumoral properties of mistletoe lectins. Mol. Med. 8 (2002) 600-606
10. Baxevanis C.N., Voutsas I.F., Soler M.H., Gritzapis A.D., Tsitsilonis O.E., Stoeva S., et al. Mistletoe lectin I-induced effects on human cytotoxic lymphocytes. I. Synergism with IL-2 in the induction of enhanced LAK cytotoxicity. Immunopharmacol. Immunotoxicol. 20 (1998) 355-372
11. Beuth J., Ko H.L., Gabius H.J., and Pulverer G. Influence of treatment with the immunomodulatory effective dose of the beta-galactoside-specific lectin from mistletoe on tumor colonization in BALB/c-mice for two experimental model systems. In Vivo 5 (1991) 29-32
12. Lavastre V., Pelletier M., Saller R., Hostanska K., and Girard D. Mechanisms involved in spontaneous and viscum album agglutinin-I-induced human neutrophil apoptosis: viscum album agglutinin-I accelerates the loss of antiapoptotic Mcl-1 expression and the degradation of cytoskeletal paxillin and vimentin proteins via caspases. J. Immunol. 168 (2002) 1419-1427
13. Morlon-Guyot J., Helmy M., Lombard-Frasca S., Pignol D., Pieroni G., and Beaumelle B. Identification of the ricin lipase site and implication in cytotoxicity. J. Biol. Chem. 278 (2003) 17006-17011
14. Kienle G.S., Berrino F., Bussing A., Portalupi E., Rosenzweig S., and Kiene H. Mistletoe in cancer-a systematic review on controlled clinical trials. Eur J. Med. Res. 8 (2003) 109-119
15. Scoffski P., Riggert S., Fumoleau F., Bolte O., Marreaud S., Lacombe D., et al. Europeen organization for research and treatment of cancer New drug development group, phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the Europeen Organization for Research and Treatment of Cancer New Drug Development Group. Ann. Oncol. 15 (2004) 1816-1824
16. Kovacs E. Serum levels of IL-12 and the production of IFN-gamma, IL-2 and IL-4 by peripheral blood mononuclear cells (PBMC) in cancer patients treated with viscum album extract. Biomed. Pharmacother. 54 (2000) 305-310
17. Stein G.M., Edlund U., Pfuller U., Bussing A., and Schietzel M. Influence of polysaccharides from Viscum album L. on human lymphocytes, monocytes and granulocytes in vitro. Anticancer Res. 19 (1999) 3907-3914
18. Ernst E., Schmidt K., and Steuer-Vogt M.K. Mistletoe for cancer? A systematic review of randomised clinical trials. Int. J. Cancer. 107 (2003) 262-267
19. Magram J., Connaughton S.E., Warrier R.R., Carvajal D.M., Wu C.Y., Ferrante J., et al. IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity 4 (1996) 471-481
20. Nicoletti A., Kaveri S., Caligiuri G., Bariety J., and Hansson G.K. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J. Clin. Invest. 102 (1998) 910-918
21. Kobayashi M., Kobayashi H., Pollard R.B., and Suzuki F. A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J. Immunol. 160 (1998) 5869-5873
22. Terao H., Harada M., Kurosawa S., Shinomiya Y., Okamoto T., Ito O., et al. Th1 type CD4+T cells may be a potent effector against poorly immunogenic syngeneic tumors. Biotherapy 8 (1994) 143-151
23. Oka H., Emori Y., Hayashi Y., and Nomoto K. Breakdown of Th cell immune responses and steroidogenic CYP11A1 expression in CD4+T cells in a murine model implanted with B16 melanoma. Cell Immunol. 206 (2000) 7-15
24. Maier G., and Fiebig H.H. Absence of tumor growth stimulation in a panel of 16 human tumor cell lines by mistletoe extracts in vitro. Anticancer Drugs 13 (2002) 373-379
25. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptative immunity. Nat. Rev. Immunol. 3 (2003) 133-146
26. Hajto T., Hostanska K., Weber K., Zinke H., Fischer J., Mengs U., et al. Effect of a recombinant lectin, Viscum album agglutinin on the secretion of interleukin-12 in cultured human peripheral blood mononuclear cells and on NK-cell-mediated cytotoxicity of rat splenocytes in vitro and in vivo. Nat. Immun. 16 (1998) 34-46
27. Gorter R.W., Joller P., and Stoss M. Cytokine release of a keratinocyte model after incubation with two different Viscum album L extracts. Am. J. Ther. 10 (2003) 40-47
28. Hulsen H., Kron R., and Mechelke F. Influence of Viscum album preparations on the natural killer cell-mediated cytotoxicity of peripheral blood. Naturwissenschaften 76 (1989) 530-531